TCM
GBT

Towercrest Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Towercrest Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,000
Closed -$205K – 76
2018
Q4 		$205K Buy
+5,000
New +$187K 0.07% 67

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Towercrest Capital Management's GBT Position: Q1 2019 in Review

Towercrest Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2019, closing a stake of 5,000 shares — an estimated $205K sold.

Towercrest Capital Management first reported a position in GBT in Q4 2018 and held it in 1 quarter. The position peaked at $205K in Q4 2018. 201 funds tracked by Wall St. Rank hold GBT as of Q1 2019.

  • Towercrest Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Towercrest Capital Management sold 5,000 Global Blood Therapeutics, Inc. shares in Q1 2019, an estimated $205K.
  • Towercrest Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Towercrest Capital Management's Global Blood Therapeutics, Inc. position peaked at $205K in Q4 2018.
  • 201 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2019.

Based on Towercrest Capital Management's 13F filing for Q1 2019, filed 15 May 2019.